{"count":8,"description":"Erudio HCP commentary reports. One report per clinical trial. Append .json or .md to any report URL for the full catalog record.","generated_at":"2026-10-08T19:15:10.421595Z","reports":[{"acronym":"PROUD-PV","counts":{"cited_sources":32,"findings":11,"people_cited":33,"people_identity_verified":26,"people_total":44,"screened_sources":33,"verified_claims":749},"depth":"rich","drugs":["ropeginterferon-alfa-2b","hydroxyurea"],"edition_number":1,"indications":["polycythemia-vera"],"links":{"html":"https://www.erudio.com/reports/proud-pv-nct01949805","json":"https://www.erudio.com/reports/proud-pv-nct01949805.json","markdown":"https://www.erudio.com/reports/proud-pv-nct01949805.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"proud-pv-01949805"}},"request":"https://www.erudio.com/contact?report=proud-pv-01949805"},"meta_description":"33 HCP sources screened · 749 verified claims from 32 sources · 11 findings. Updated 2026-10-08.","nct_id":"NCT01949805","offer":{"currency":"USD","one_off_usd":1250,"size":"standard"},"phase":["PHASE3"],"publication_state":"public","slug":"proud-pv-01949805","sponsor":"AOP Orphan Pharmaceuticals AG","therapeutic_area":["hematology"],"title":"A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera","updated_at":"2026-10-08T19:15:10.421595Z","version":"1.0.0"},{"acronym":"NEONIPIGA","counts":{"cited_sources":61,"findings":12,"people_cited":72,"people_identity_verified":66,"people_total":91,"screened_sources":68,"verified_claims":1222},"depth":"rich","drugs":["nivolumab","ipilimumab"],"edition_number":1,"indications":["gastroesophageal-adenocarcinoma"],"links":{"html":"https://www.erudio.com/reports/neonipiga-nct04006262","json":"https://www.erudio.com/reports/neonipiga-nct04006262.json","markdown":"https://www.erudio.com/reports/neonipiga-nct04006262.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"neonipiga-04006262"}},"request":"https://www.erudio.com/contact?report=neonipiga-04006262"},"meta_description":"68 HCP sources screened · 1222 verified claims from 61 sources · 12 findings. Updated 2026-10-08.","nct_id":"NCT04006262","offer":{"currency":"USD","one_off_usd":1950,"size":"deep"},"phase":["PHASE2"],"publication_state":"public","slug":"neonipiga-04006262","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","therapeutic_area":["oncology"],"title":"Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma: An Open-label GERCOR Phase II Study","updated_at":"2026-10-08T16:02:35.345256Z","version":"1.0.0"},{"acronym":null,"counts":{"cited_sources":28,"findings":13,"people_cited":38,"people_identity_verified":36,"people_total":47,"screened_sources":41,"verified_claims":1065},"depth":"standard","drugs":["cyclophosphamide","dexamethasone"],"edition_number":1,"indications":["leukemia"],"links":{"html":"https://www.erudio.com/reports/calgb-10403-nct00558519","json":"https://www.erudio.com/reports/calgb-10403-nct00558519.json","markdown":"https://www.erudio.com/reports/calgb-10403-nct00558519.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"calgb-10403-00558519"}},"request":"https://www.erudio.com/contact?report=calgb-10403-00558519"},"meta_description":"41 HCP sources screened · 1065 verified claims from 28 sources · 13 findings. Updated 2026-10-08.","nct_id":"NCT00558519","offer":{"currency":"USD","one_off_usd":1250,"size":"standard"},"phase":["PHASE2"],"publication_state":"public","slug":"calgb-10403-00558519","sponsor":"Alliance for Clinical Trials in Oncology","therapeutic_area":["oncology"],"title":"An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)","updated_at":"2026-10-08T06:48:21.724185Z","version":"1.0.0"},{"acronym":"MARS2","counts":{"cited_sources":134,"findings":12,"people_cited":98,"people_identity_verified":114,"people_total":141,"screened_sources":165,"verified_claims":1094},"depth":"rich","drugs":[],"edition_number":1,"indications":["mesothelioma"],"links":{"html":"https://www.erudio.com/reports/mars2-nct02040272","json":"https://www.erudio.com/reports/mars2-nct02040272.json","markdown":"https://www.erudio.com/reports/mars2-nct02040272.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"mars2-02040272"}},"request":"https://www.erudio.com/contact?report=mars2-02040272"},"meta_description":"165 HCP sources screened · 1094 verified claims from 134 sources · 12 findings. Updated 2026-10-08.","nct_id":"NCT02040272","offer":{"currency":"USD","one_off_usd":1950,"size":"deep"},"phase":["NA"],"publication_state":"public","slug":"mars2-02040272","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","therapeutic_area":["oncology"],"title":"Mesothelioma and Radical Surgery 2: a Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no (Extended) Pleurectomy Decortication for Patients With Malignant Pleural Mesothelioma (Mars 2).","updated_at":"2026-10-08T06:14:35.349644Z","version":"1.0.0"},{"acronym":"EURTAC","counts":{"cited_sources":9,"findings":9,"people_cited":16,"people_identity_verified":17,"people_total":30,"screened_sources":12,"verified_claims":210},"depth":"thin","drugs":["carboplatin","docetaxel","cisplatin"],"edition_number":1,"indications":["non-small-cell-lung-cancer"],"links":{"html":"https://www.erudio.com/reports/eurtac-nct00446225","json":"https://www.erudio.com/reports/eurtac-nct00446225.json","markdown":"https://www.erudio.com/reports/eurtac-nct00446225.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"eurtac-00446225"}},"request":"https://www.erudio.com/contact?report=eurtac-00446225"},"meta_description":"12 HCP sources screened · 210 verified claims from 9 sources · 9 findings. Updated 2026-10-08.","nct_id":"NCT00446225","offer":{"currency":"USD","one_off_usd":750,"size":"focused"},"phase":["PHASE3"],"publication_state":"public","slug":"eurtac-00446225","sponsor":"Spanish Lung Cancer Group","therapeutic_area":["oncology"],"title":"Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR","updated_at":"2026-10-08T03:47:17.775241Z","version":"1.0.0"},{"acronym":"SURTIME","counts":{"cited_sources":32,"findings":13,"people_cited":38,"people_identity_verified":53,"people_total":65,"screened_sources":34,"verified_claims":427},"depth":"rich","drugs":[],"edition_number":1,"indications":["renal-cell-carcinoma"],"links":{"html":"https://www.erudio.com/reports/surtime-nct01099423","json":"https://www.erudio.com/reports/surtime-nct01099423.json","markdown":"https://www.erudio.com/reports/surtime-nct01099423.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"surtime-01099423"}},"request":"https://www.erudio.com/contact?report=surtime-01099423"},"meta_description":"34 HCP sources screened · 427 verified claims from 32 sources · 13 findings. Updated 2026-10-08.","nct_id":"NCT01099423","offer":{"currency":"USD","one_off_usd":1250,"size":"standard"},"phase":["PHASE3"],"publication_state":"public","slug":"surtime-01099423","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","therapeutic_area":["oncology"],"title":"Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma","updated_at":"2026-10-08T02:08:11.487997Z","version":"1.0.0"},{"acronym":null,"counts":{"cited_sources":36,"findings":12,"people_cited":35,"people_identity_verified":10,"people_total":23,"screened_sources":37,"verified_claims":499},"depth":"rich","drugs":[],"edition_number":1,"indications":["melanoma"],"links":{"html":"https://www.erudio.com/reports/mslt-ii-nct00297895","json":"https://www.erudio.com/reports/mslt-ii-nct00297895.json","markdown":"https://www.erudio.com/reports/mslt-ii-nct00297895.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"mslt-ii-00297895"}},"request":"https://www.erudio.com/contact?report=mslt-ii-00297895"},"meta_description":"37 HCP sources screened · 499 verified claims from 36 sources · 12 findings. Updated 2026-10-08.","nct_id":"NCT00297895","offer":{"currency":"USD","one_off_usd":1250,"size":"standard"},"phase":["NA"],"publication_state":"public","slug":"mslt-ii-00297895","sponsor":"Saint John's Cancer Institute","therapeutic_area":["oncology"],"title":"A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node","updated_at":"2026-10-08T00:48:21.930953Z","version":"1.0.0"},{"acronym":null,"counts":{"cited_sources":9,"findings":8,"people_cited":13,"people_identity_verified":24,"people_total":29,"screened_sources":9,"verified_claims":116},"depth":"thin","drugs":["carboplatin","cisplatin","pembrolizumab"],"edition_number":1,"indications":["head-and-neck-squamous-cell-carcinoma"],"links":{"html":"https://www.erudio.com/reports/ea3191-nct04671667","json":"https://www.erudio.com/reports/ea3191-nct04671667.json","markdown":"https://www.erudio.com/reports/ea3191-nct04671667.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"ea3191-04671667"}},"request":"https://www.erudio.com/contact?report=ea3191-04671667"},"meta_description":"9 HCP sources screened · 116 verified claims from 9 sources · 8 findings. Updated 2026-10-07.","nct_id":"NCT04671667","offer":{"currency":"USD","one_off_usd":750,"size":"focused"},"phase":["PHASE2"],"publication_state":"public","slug":"ea3191-04671667","sponsor":"National Cancer Institute (NCI)","therapeutic_area":["oncology"],"title":"A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features","updated_at":"2026-10-07T21:39:01.340971Z","version":"1.0.0"}],"schema":"erudio.catalog_record","schema_version":"1.0"}